Navigation Links
BioLineRx Presents Data on BL-1040 at Cardiovascular,Revascularization Therapies Conference Demonstrating Potential to,Reduce Deterioration of Infarcted Heart Tissue and Maintain,Functionality

JERUSALEM--(BUSINESS WIRE)--Mar 7, 2007 - BioLineRx Ltd. (TASE:BLRX), Israel's leading drug development company, reported today pre-clinical data from trials of BL-1040 demonstrating that BL-1040 is effective in preventing deterioration of the myocardium after a myocardial infarction (MI), thereby reducing left ventricle dilatation and eventual heart failure in a pig model. Professor Jonathan Leor, MD, Director of the Neufeld Cardiac Research Institute at Sheba Medical Center in Israel, presented pre-clinical data on BL-1040 at the Cardiovascular Revascularization Therapies (CRT) conference, held March 7-9, 2007 in Washington, D.C.

"We are encouraged by these results, as BL-1040 is the first injectable liquid polymer being developed to provide mechanical support to damaged heart tissues following MI. The data so far have shown that this therapy may increase cardiac performance or contractility and prevent further damage," stated Professor Leor.

"We believe there is a great unmet medical need for this product to prevent cardiac tissue damage in the risky period following heart attack," commented Morris C. Laster, MD, CEO of BioLineRx. "We look forward to advancing BL-1040 to Phase I/II trials in the second quarter of 2007 and plan to work closely with the U.S. FDA medical devices division to determine the clinical plan for BL-1040."

The data presented at the CRT conference comprised a study in 21 pigs that underwent an acute MI, and then received an intra-coronary administration of BL-1040. The results showed that BL-1040 attenuated infarct expansion and prevented left ventricle dilatation. The intracoronary administration of BL-1040 was feasible and safe, without causing arrhythmias, toxic effects or vascular obstruction.

About BL-1040

BL-1040 is a biodegradable liquid polymer intended to provide mechanical support to damaged heart tissue and increase cardiac output. BL-1040 is admin istered via the coronary artery, as a liquid that is injected during catheterization into the damaged heart muscle. The liquid polymerizes within the tissue and forms a protective scaffold that enhances the mechanical strength of the heart muscle during recovery and repair thereby preventing pathological enlargement of the left ventricle after the heart attack. BL-1040 degrades naturally six weeks after injection.

Patients who have undergone an acute MI (AMI) with severe heart damage are the most likely to benefit from BL-1040. Approximately 40% of AMI patients develop left ventricle dilatation or heart failure, which carries a substantially greater mortality risk. This population includes approximately 380,000 patients in the U.S., with a total estimated U.S. market of over $1.5 billion.

BL-1040 was in-licensed from Ben-Gurion University through its business company BGN Technologies, and was developed by Professor Smadar Cohen and Professor Jonathan Leor from the Department of Biotech and Biomedical Engineering at Ben-Gurion University.

About BioLineRx

BioLineRx, a clinical stage drug development company traded on the Tel Aviv Stock Exchange (BLRX), is dedicated to building a robust pipeline of promising therapeutics for unmet medical needs. The Company's current product pipeline consists of 10 compounds, 3 of which are in or impending clinical trials. Its lead product, BL-1020, for the treatment of schizophrenia, successfully completed Phase 1 clinical trials; and BL-1040, for the treatment of damaged heart tissue post myocardial infarction, is expected to enter the clinic in the second quarter of 2007. Additional products under development include compounds for the treatment of cancer and CNS, cardiovascular, metabolic, infectious and autoimmune diseases.

BioLineRx advances projects from early stage discovery and lead generation to advanced clinical trials, regulatory approval and marketing. Partnering with researchers, universi ties and biotech companies to further the commercialization of promising compounds, BioLineRx seeks to enrich the pipeline of large pharmaceutical companies seeking their next blockbuster drugs. The Company was founded in 2003 by leaders in the Israeli life science arena including Teva Pharmaceuticals Ltd, Giza, Pitango, Hadasit and the Jerusalem Development Authority. For more information, please visit www.biolinerx.com.

Contact

BioLineRx Ltd.
Yuri Shoshan, +972-2-548-9100
VP Finance and Corporate Development
yuri@biolinerx.com
or
Media Liaison, BioLineRx Ltd.
Tsipi Haitovsky, +972-52-598-9892
tsipih@biolinerx.com
or
Stern Investor Relations, Inc.
Melanie Friedman, 212-362-1200
melanie@sternir.com


'"/>




Related medicine technology :

1. BioLineRx Presents Data From Successful Phase I Trial for BL-1020 in Schizophrenia at American Psychiatric Association Conference
2. BioLineRx Presents Phase I Clinical Data of BL-1020 at Upcoming Clinical Conferences
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... February 12, 2016 ... vermerkt)   http://www.sedar.com ) und ... abrufbar.    --> http://www.sedar.com ... http://www.telestatherapeutics.com abrufbar.    --> ... heute seinen Konzernabschluss des zweiten Quartals ...
(Date:2/12/2016)...  Memorial Hermann Health System has teamed up with ... bring a one-of-a-kind experience to pediatric patients at ... as 360-degree video and Google Cardboard, Howard was able ... giving the patients and their families an unexpected, and ... on video . Memorial Hermann IRONMAN ...
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company ... Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent would ... the UK, France , Italy ... to dilute the product only with dextrose solution.  ... 2015, the UK Court of Appeal held that Lilly,s patent ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... , ... Valentine’s Day is nearly upon us, and most singles could probably ... flawless hair, and a sparkling personality are all well and good, but if somebody ... home with Rover. (Actually, man’s best friend might not even want to be near ...
(Date:2/13/2016)... ... February 13, 2016 , ... In its newly ... vein visualization technology should be used to ensure patient safety when placing an ... INS Standards mandate the use of vein visualization technology in patients with difficult ...
(Date:2/12/2016)... ... 12, 2016 , ... According to an article published February 4th ... significant portion of hernia repairs throughout the United States. Commenting on this article, Beverly ... that this trend has not only been expected, but it seems to be a ...
(Date:2/12/2016)... ... February 12, 2016 , ... CDRH Enforcement Trends: , Back to the Future , ... , As Winston Churchill said, “Those who don’t learn from history are doomed to ... expect when they come knocking this year. But that takes time. , Take a ...
(Date:2/12/2016)... ... February 12, 2016 , ... T.E.N., a ... closed for the ISE Southeast Awards 2016. Finalists and winners of the ISE® ... Southeast Executive Forum and Awards Gala on March 15, 2016 at the Westin ...
Breaking Medicine News(10 mins):